Wolfram E. Samlowski

5.4k total citations
154 papers, 3.7k citations indexed

About

Wolfram E. Samlowski is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wolfram E. Samlowski has authored 154 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 49 papers in Molecular Biology and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wolfram E. Samlowski's work include Cancer Immunotherapy and Biomarkers (21 papers), Cutaneous Melanoma Detection and Management (20 papers) and Cancer Genomics and Diagnostics (17 papers). Wolfram E. Samlowski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Cutaneous Melanoma Detection and Management (20 papers) and Cancer Genomics and Diagnostics (17 papers). Wolfram E. Samlowski collaborates with scholars based in United States, South Korea and United Kingdom. Wolfram E. Samlowski's co-authors include John R. McGregor, John B. Hibbs, Sancy A. Leachman, Raymond A. Daynes, Chang‐Yeol Yim, Steven O’Day, Neil R. Bastian, Kenneth M. Boucher, Evan M. Hersh and Lee D. Cranmer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Wolfram E. Samlowski

151 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wolfram E. Samlowski United States 34 1.6k 1.5k 848 680 349 154 3.7k
Kah Keng Wong Malaysia 27 1.3k 0.8× 1.6k 1.1× 506 0.6× 1.1k 1.5× 307 0.9× 111 3.7k
Wolfgang Hilbe Austria 33 1.3k 0.8× 1.2k 0.8× 349 0.4× 794 1.2× 448 1.3× 129 3.9k
Rocco Savino Italy 35 2.1k 1.3× 2.4k 1.7× 1.0k 1.2× 433 0.6× 525 1.5× 83 5.1k
Wolfgang Doppler Austria 38 1.6k 1.0× 2.1k 1.5× 987 1.2× 250 0.4× 559 1.6× 90 4.2k
John J. Rinehart United States 27 988 0.6× 1.0k 0.7× 568 0.7× 461 0.7× 234 0.7× 67 2.9k
David Propper United Kingdom 24 1.3k 0.8× 1.1k 0.8× 662 0.8× 374 0.6× 532 1.5× 78 3.1k
Trivadi S. Ganesan India 32 1.2k 0.8× 1.7k 1.2× 529 0.6× 365 0.5× 590 1.7× 166 3.8k
Carlos Muro‐Cacho United States 30 2.1k 1.3× 1.9k 1.3× 1.1k 1.3× 563 0.8× 587 1.7× 85 4.5k
Alberto Abbruzzese Italy 36 1.1k 0.7× 1.3k 0.9× 393 0.5× 433 0.6× 362 1.0× 82 3.3k
Takashi Kijima Japan 26 1.4k 0.9× 1.3k 0.9× 392 0.5× 1.2k 1.8× 320 0.9× 167 3.4k

Countries citing papers authored by Wolfram E. Samlowski

Since Specialization
Citations

This map shows the geographic impact of Wolfram E. Samlowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfram E. Samlowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfram E. Samlowski more than expected).

Fields of papers citing papers by Wolfram E. Samlowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfram E. Samlowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfram E. Samlowski. The network helps show where Wolfram E. Samlowski may publish in the future.

Co-authorship network of co-authors of Wolfram E. Samlowski

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfram E. Samlowski. A scholar is included among the top collaborators of Wolfram E. Samlowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfram E. Samlowski. Wolfram E. Samlowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Samlowski, Wolfram E., et al.. (2024). Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report. Frontiers in Oncology. 14. 1301424–1301424. 4 indexed citations
5.
Patel, Sandip Pravin, Megan Othus, Young Kwang Chae, et al.. (2023). A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clinical Cancer Research. 30(1). 33–38. 15 indexed citations
6.
Samlowski, Wolfram E., et al.. (2023). Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series. Oncotarget. 14(1). 709–718. 8 indexed citations
7.
Samlowski, Wolfram E., Nicholas J. Robert, Liwei Chen, et al.. (2022). Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Medicine. 12(3). 2378–2388. 3 indexed citations
8.
Samlowski, Wolfram E., et al.. (2022). Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data. Biomedicines. 10(5). 1144–1144. 15 indexed citations
9.
Samlowski, Wolfram E., Michelle Silver, Shujing Zhang, et al.. (2022). Real-world Clinical Outcomes of Patients with Stage IIB or IIC Cutaneous Melanoma Treated at US Community Oncology Clinics. Future Oncology. 18(33). 3755–3767. 4 indexed citations
11.
Samlowski, Wolfram E., et al.. (2021). Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series. The Oncologist. 26(12). e2247–e2253. 17 indexed citations
12.
Samlowski, Wolfram E., James Moon, Michael B. Atkins, et al.. (2017). High frequency of brain metastases after adjuvant therapy for high‐risk melanoma. Cancer Medicine. 6(11). 2576–2585. 24 indexed citations
13.
Vogelzang, Nicholas J., Sylvia Adams, Carol Aghajanian, et al.. (2011). Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology. 30(1). 88–109. 68 indexed citations
15.
Samlowski, Wolfram E., Martin Majer, Kenneth M. Boucher, et al.. (2008). Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 113(9). 2539–2548. 33 indexed citations
16.
Samlowski, Wolfram E., Gordon A. Watson, Michael Wang, et al.. (2007). Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 109(9). 1855–1862. 64 indexed citations
17.
Alexandrescu, Doru T, Karl D. Lewis, Wolfram E. Samlowski, et al.. (2007). A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.. Molecular Cancer Therapeutics. 6. 4 indexed citations
18.
Lewis, Tracey, John Elder Robison, Roy R. L. Bastien, et al.. (2005). Molecular classification of melanoma using real‐time quantitative reverse transcriptase‐polymerase chain reaction. Cancer. 104(8). 1678–1686. 49 indexed citations
19.
Samlowski, Wolfram E., et al.. (1995). Effectiveness and Toxicity of Protracted Nitric Oxide Synthesis Inhibition During IL-2 Treatment of Mice. Journal of Immunotherapy. 18(3). 166–178. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026